News | December 21, 2025
Bristol Myers Squibb to provide Eliquis free to Medicaid
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
India plays a critical role in Bristol Myers Squibb’s global strategy
The FDA aims to make a decision by April 8, 2026
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
The company is excluding data from the affected sites to maintain the study's integrity
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries
Subscribe To Our Newsletter & Stay Updated
